Leonardo Mirandola

Leonardo Mirandola, PhD has a diverse work experience in the biotechnology and pharmaceutical industries. Leonardo is currently serving as the Interim Chief Operations Officer and Chief Scientific Officer at Kiromic Biopharma, Inc., a position they have held since May 2023 and July 2022, respectively. Previously, they served as the Vice President of Research and Development at the same company from September 2021 to July 2022, and as the Head of Clinical Translation from February 2021 to September 2021.

In addition to their roles at Kiromic Biopharma, Inc., Mirandola has also worked as an Associate Editor at Cancer Immunity and Immunotherapy since December 2022. Prior to that, they were a self-employed consultant in biotechnology, pharmaceuticals, and life sciences from July 2019 to February 2021.

Mirandola's earlier experience includes positions at Kiromic, Inc., where they served as the Director of Clinical Operations from August 2018 to July 2019, and as the Executive Director from May 2016 to July 2019. In these roles, they oversaw clinical operations quality systems, directed cGMP manufacturing processes, and contributed to the development of new cellular and molecular immunology techniques.

Before joining Kiromic, Inc., Mirandola worked as a Post-Doctoral Researcher at Texas Tech University Health Sciences Center from September 2013 to March 2016. Their research focused on cancer/testis antigens and imaging of ovarian cancer, as well as the efficacy of oral vaccines for ovarian cancer in murine models.

Mirandola's earliest work experience was as a Postdoc Research Associate at the University of Milan, Dep. of Medicine, Surgery and Dentistry, Molecular Pathology Lab from February 2010 to September 2013. Their research involved studying the molecular mechanisms of Notch-mediated signals in hematological malignancies, such as acute leukemias and multiple myeloma. Leonardo also worked as a Teaching Assistant during this time and completed their PhD in November 2009.

Overall, Leonardo Mirandola, PhD has an extensive and varied work experience in research, development, clinical operations, and leadership positions in the biotechnology and pharmaceutical industries.

Leonardo Mirandola, PhD obtained their Doctor of Philosophy (PhD) degree in Molecular Medicine from Università degli Studi di Milano, where they studied from 2006 to 2009. Prior to that, they completed their undergraduate education at the University of Milan, earning a degree in Medical Biotechnology with full marks and honors from 2001 to 2006.

Additionally, they pursued further education and research at Texas Tech University Health Sciences Center, specializing in the field of Immunology. While at the university, they completed a post-doctoral program in Immunology, although the specific duration of this program is not specified.